Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation has marked World Diabetes Day and the second anniversary of its Together on Diabetes™ initiative by issuing the initiative's second annual report and awarding two new grants to partners in India.

In its first two years, Together on Diabetes has awarded $43.2 million to 21 grantees working in 28 states and more than 50 communities in the United States. Since the expansion of the initiative to China and India in May 2012, $3.37 million has been awarded for seven projects in those countries. China, India and the U.S. have the most people living with diabetes.

"We are enormously proud of the work of our Together on Diabetes grantees and partners," said John Damonti, president, Bristol-Myers Squibb Foundation. "They are engendering hope in those hardest hit by the diabetes epidemic and transforming communities so that the healthy choice is an easier choice for the person living with type 2 diabetes."

Together on Diabetes' second annual report provides an update on the Foundation’s grantmaking and profiles how the innovative projects are helping people living with diabetes to improve control of their disease and how communities are coming together to make diabetes information and supportive services more visible, accessible, navigable, culturally competent and integrated with clinical care. The report also captures initial results and early lessons from the projects.

Two new Together on Diabetes grants in India support programs in Jodhpur and Mumbai:

  • Humana People to People will receive US $355,991 over two years to reduce diabetes-related morbidity and mortality and prevent the onset of type 2 diabetes among those at increased risk for the disease through timely intervention and home-based diabetes care.
  • United Way Mumbai Helpline will receive US $205,362 over two years to use community-based lifestyle interventions for the prevention, early detection and management of type 2 diabetes among working adults and municipal and public school workers in Mumbai.

About Together on Diabetes
Together on Diabetes is a five-year, $115 million initiative launched in November 2010 by the Bristol-Myers Squibb Foundation to improve health outcomes of people living with type 2 diabetes in China, India and the United States by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, this initiative targets adult populations disproportionately affected by the disease.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...